TScan reports Q1 2024 results: net loss $30.1M, first solid tumor patient dosed, heme patients relapse-free

TScan Therapeutics, Inc.

2024-Q1 EPS reported -$0.32 revenue$566,000

Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.
First patient dosed in Phase 1 solid tumor trial with TSC-203-A0201 targeting PRAME; initial data expected H2 2024.
All eight heme treatment-arm patients relapse-free with median follow-up >10 months; two control patients relapsed.
Closed upsized $167.8M public offering in April; cash and marketable securities $162.8M at March 31, extending runway to Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.

Period: the first quarter ended March 31, 2024
Revenue: $0.6 million
Result: reported results

Exact text from the filing

• Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.